This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Sand, Peter
| Item Type | Name |
|
Concept
|
Muscarinic Antagonists
|
|
Academic Article
|
Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.
|
|
Academic Article
|
Elevating our therapeutic expectations in overactive bladder.
|
|
Academic Article
|
Oxybutynin for treatment of urge urinary incontinence and overactive bladder: an updated review.
|
|
Academic Article
|
Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial.
|
|
Academic Article
|
The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial.
|
|
Academic Article
|
Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
|
|
Academic Article
|
Nocturia: etiology, diagnosis, and treatment.
|
|
Academic Article
|
Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
|
|
Academic Article
|
Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials.
|
|
Academic Article
|
Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials.
|
|
Academic Article
|
Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome.
|
|
Academic Article
|
Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study.
|
|
Academic Article
|
Evaluation and treatment of female urinary incontinence.
|
|
Academic Article
|
Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference.
|
|
Academic Article
|
Long-term safety, tolerability and efficacy of fesoterodine in subjects with overactive bladder symptoms stratified by age: pooled analysis of two open-label extension studies.
|
|
Academic Article
|
The evolution of transdermal therapy for overactive bladder.
|
|
Academic Article
|
Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms.
|
|
Academic Article
|
Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome.
|
|
Academic Article
|
Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged = 75 years) with overactive bladder syndrome.
|
|
Academic Article
|
Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
|
|
Academic Article
|
Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin.
|
|
Academic Article
|
Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.
|
|
Academic Article
|
Efficacy and tolerability of fesoterodine in women with overactive bladder.
|
|
Academic Article
|
Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement?
|
|
Academic Article
|
Oxybutynin: past, present, and future.
|